Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study

Abstract

SESSION TITLE COPD ISESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting [beta]2-agonist (indacaterol) and long-acting muscarinic antagonist glycopyrronium, for the treatment of COPD. We evaluated the overall rate of exacerbations and the health status with QVA149 in comparison with glycopyrronium and tiotropium. METHODS: In this 64-week multicenter study, patients aged >=40 yrs with severe-to-very severe COPD were randomized to receive once-daily, double-blind QVA149 110/50 [mu]g, glycopyrronium 50 [mu]g, or open-label tiotropium 18 [mu]g. Overall exacerbation rates and health status via the St George's Respiratory Questionnaire (SGRQ) scores were determined. RESULTS: Of 2224 patients randomized, 75% of patients completed the study. QVA149 resulted in a rate reduction of 15% versus glycopyrronium (Rate ratio [RR] 0.85; 95% CI 0.77-0.94; p=0.001) and 14% versus tiotropium (RR 0.86; 95% CI 0.78-0.94; p